# 99mTc-HPArk2 SPECT/CT for the Detection of HER2-positive Breast Cancer

> **NCT04267900** · EARLY_PHASE1 · COMPLETED · sponsor: **Peking Union Medical College Hospital** · enrollment: 34 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** 99mTc-HPArk2

## Key facts

- **NCT ID:** NCT04267900
- **Lead sponsor:** Peking Union Medical College Hospital
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-12-07
- **Primary completion:** 2020-12-31
- **Final completion:** 2020-12-31
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2022-09-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04267900

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04267900, "99mTc-HPArk2 SPECT/CT for the Detection of HER2-positive Breast Cancer". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT04267900. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*